Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR845 (Difelikefalin) Phase 2a in Osteoarthritis
NCT02524197Phase 2Completed
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Aug 2015
- Primary completion
- Jan 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of difelikefalin in osteoarthritis (OA) (4 arms), sponsored by Cara Therapeutics, Inc. Primary endpoint: Safety and Tolerability of orally-administered CR845 at 38 days. Started Aug 2015; status: completed.
02
Drugs
difelikefalin
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02524197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524197.